^
Association details:
| Biomarker: | EGFR L858R + EGFR L718Q |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | BI-4020 (EGFR inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
EP08.02-085 In vitro Activity and Potential Resistance Mutations Against BI-4020, a 4th-generation EGFR-TKI
Published date:
07/12/2022
Excerpt:
We observed that BI-4020 was active against Ba/F3 cells with EGFR exon 19 deletion (Del19) or L858R mutation...only E709G and L718Q conferred high-level resistance to BI-4020 when L858R was present as a sensitizing mutation.
